Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, Campone M, Petrakova K, Blackwell K, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Journal Of Clinical Oncology 2017, 35: 1038-1038. DOI: 10.1200/jco.2017.35.15_suppl.1038.Peer-Reviewed Original ResearchAdvanced breast cancerProgression-free survivalMONALEESA-2Treatment benefitInterim analysisHER2- ABCLET armEndocrine therapyPostmenopausal womenGrade 3/4 laboratory abnormalitiesFirst-line ribociclibElevated alanine aminotransferasePhase 3 trialSecond interim analysisFirst-line treatmentFirst interim analysisET resistancePFS ratesPrimary endpointPrior therapySecondary endpointsLaboratory abnormalitiesMedian durationOverall survivalPFS events